The early weeks and dose step-ups are exactly when people are most likely to forget a dose or lose track of how they are feeling, and that is the same window when side effects (and fluid loss) peak
The healthcare professional ensures the patient is comfortable and safe
Multi-Agonist Peptides and Combination Approaches Researchers are working on multi-agonist peptides that interact with several receptors, including GLP1, GIP, and glucagon
Quantitative synthesis included frequency counts and cross-tabulations to describe the number and type of studies per outcome domain (eGFR slope, albuminuria, composite kidney outcomes, safety)
2 Lower doses, such as 0.25 mg, 0.5 mg, and 1 mg, are designed as dose increases to help people reach 2.4 mg, not maintenance doses for weight management